Black solar panel lowered onto its rail on a tiled roof, the installer crouched seen from behind in a blue harness
Cleo
All services →
Online toolsYou have a regulatory team
Product compliance assessmentThe legislation that applies to your product, what is still missing and what to do, per product and per market.Product monitoringSee the demo →The texts that apply to your products and the ones that change, within the agreed monitoring scope.
Not sure which option fits? We can help you choose.Free consultation →
Turnkey servicesYou have no one in-house
CE markingTechnical documentation and draft EU declaration of conformity, which the manufacturer signs.EU authorised representativeAn operator established in the Union to sell your products in Europe: written mandate, address, file, authorities.
Case studiesWork we have done with our clientsBlogRegulatory news and analysisRegulatory atlasThe official sources we track, country by country
About
EN·FRWhatsAppBook a demoGet started→
resources / Product Compliance

20 August 2026 · 6 min read · by Naomie Halioua

↖ all articlesNaomie HaliouaNaomie Halioua
Co-founder & CTO, AI Research
20 August 2026 · 6 min readProduct Compliance

A question about your product’s compliance?

Tell us about your product and the markets you want to enter.

WhatsApp ↗Free consultation ↗

On 12 August, Saudi Arabia banned syringe-shaped cosmetics outright: the same injectable-look serum packaged as an ampoule or vial stays legal, if its label now says, in Arabic and English, do not inject

On 12 August 2026, Saudi Arabia's Food and Drug Authority (SFDA) issued a circular prohibiting the circulation of cosmetic products for external use that are packaged in forms resembling pharmaceutical injectables. Most coverage reduced this to one headline: Saudi Arabia bans syringe cosmetics. That headline describes only one branch of the circular. Syringe-style packaging is banned outright, with no compliance path back to market. Ampoules and vials, the packaging format behind the "skin booster" and collagen-serum products that have become a fixture of prestige skincare shelves across the Gulf, are not banned at all. They stay legal, provided their inner and outer packaging carries a new bilingual Arabic-and-English warning that the product is for external cosmetic use only, must not be injected, should avoid contact with the eyes, and should be opened with care. Manufacturers, importers and other establishments have until 31 December 2026, under five months from the circular becoming public, to pull noncompliant stock or relabel it. The ban itself starts the very next day, 1 January 2027.

A packaging shape, not a formula, decides the rule

The SFDA circular targets cosmetic products for external use whose packaging resembles that of injectable pharmaceuticals: syringes, ampoules and vials. It splits into two tracks. Syringe-style applicators, the format used for skin-booster serums marketed to mimic a clinic-grade injectable treatment, are prohibited from circulation altogether, with no labeling fix available to bring one back into compliance. Ampoules and vials, the glass or plastic single-dose containers that dominate the region's dermocosmetic serum category, remain permitted, but only once their inner and outer packaging carries a bilingual Arabic-and-English warning: for external cosmetic use only, not for injection, avoid contact with the eyes, exercise caution when opening. The circular separately bars advertising, promotional or marketing material for these products from stating or implying that they can be administered by injection or by any other device that penetrates the skin, which pulls campaign copy and influencer briefs into the same compliance perimeter as the physical label. The SFDA has said establishments that miss the 31 December 2026 deadline face legal action.

Three nuances that separate signal from noise

01

The ban is a packaging category, not an ingredient list

SFDA's rule turns on the shape of the container, not what is inside it. A collagen or hyaluronic-acid serum in a syringe applicator is banned outright; the identical formula filled into an ampoule or vial only needs a new label to stay on shelves.

02

The deadline covers stock already on shelves

The circular does not grandfather cosmetics that already hold an SFDA marketing notification: manufacturers, importers and other establishments must withdraw or fix any covered product already in circulation by 31 December 2026, not just new listings filed after the circular.

03

The marketing copy is now inside the compliance file

It is not only the physical label that changes. SFDA separately bars advertising, promotional and marketing material for these products from stating or implying injectable administration, extending the rule to campaign copy and influencer content, not just the packaging itself.

12 Aug 2026

SFDA's circular becomes public: syringe-style cosmetic packaging is banned outright, and ampoules and vials must carry a new bilingual Arabic-and-English warning to stay in circulation.

Following days

Gulf and Saudi outlets report the circular, most under headlines describing a blanket ban, with less attention to the ampoule-and-vial labeling track that keeps those formats on the market.

By 31 Dec 2026

Grace period: manufacturers, importers and establishments must withdraw noncompliant stock, including products already carrying a valid SFDA marketing notification, or bring packaging, labels and marketing material into line.

From 1 Jan 2027

The ban and the new labeling requirements take legal effect. SFDA has said it will pursue legal action against products and establishments that remain noncompliant.

The numbers behind 12 August

One number is how much of the product the circular actually touches. One is how many languages a single warning label must now carry. The third is how much runway sits between the compliance deadline and the day the ban takes legal effect.

0

formula or ingredient changes required by the circular: it regulates packaging form, labeling and marketing claims only, leaving a compliant serum's actual composition untouched

2 languages

Arabic and English, both mandatory on the new warning that ampoule and vial packaging must carry, on the inner container and the outer box alike

1 day

the gap between the grace-period deadline, 31 December 2026, and the day the ban and labeling requirements become legally enforceable, 1 January 2027

The real subject: the compliance trigger sits outside the formulation file

Brands scaling a global skin-booster or collagen-serum line typically build their compliance file around the formulation: allergen thresholds, restricted-substance limits, concentration caps, the questions an ingredient-level regulatory review answers market by market. SFDA's circular does not touch any of that. It regulates the container the formula sits in, and separately, the words used to sell it. A serum that clears every ingredient and labeling check in the EU, the US or a brand's home market can still be non-compliant in Saudi Arabia purely because its applicator is styled like a syringe, and a brand that never changed a single ingredient can face a Saudi-only packaging, label and marketing-copy workstream it did not previously need. That is a different axis of compliance than the one most cosmetics regulatory files are built to track: a classification that runs on the container's silhouette and the claims made around it, not on what the container holds.

Why it matters for brands

For any skincare or beauty brand selling skin-booster, collagen-serum or similarly injectable-styled products into Saudi Arabia, directly or through a distributor, three things follow from 12 August. First, audit stock by packaging format, not by formulation: a syringe-style SKU has no path back to compliance in this market and needs a different applicator or an exit from Saudi shelves, while an ampoule or vial SKU only needs a relabel, and treating the two as one problem wastes the shorter runway the relabel option actually has. Second, extend the review past the physical product: SFDA's bar on advertising or marketing that states or implies injectable use covers campaign photography, product copy and influencer briefs, so a compliant new label paired with an unchanged ad claiming a "clinic-grade injection" effect is still a breach. Third, treat the 31 December 2026 deadline as covering everything already in Saudi distribution, not only future launches: an existing SFDA marketing notification does not exempt a product from the packaging and labeling rule, so brands need a per-SKU packaging audit now, under five months out from the circular, rather than waiting for the next renewal cycle to catch it.

Two ways to read 12 August

The narrow read

Saudi Arabia's SFDA banned syringe-style cosmetics to stop them being mistaken for injectable drugs.

The structural read

SFDA split one product family into two legal fates by container shape alone, then reached into stock already on shelves and into marketing copy to close the gap, leaving brands under five months to sort SKUs by applicator, not by formula.

Sources

  1. Saudi Food and Drug Authority (SFDA): Circulars index
  2. Saudi Gazette: "SFDA bans cosmetic products packaged as syringes, ampoules, and vials"
  3. Gulf News: "Saudi Arabia bans syringe-style cosmetic packaging from 2027 to prevent confusion with injectable drugs"
  4. Gulf Insider: "SFDA bans cosmetic products packaged as syringes, ampoules, and vials"
  5. ProPakistani: "Saudi Arabia Bans Specific Beauty Products", 12 August 2026
  6. Harper's Bazaar Arabia: "Saudi Arabia Bans Syringe-Style Cosmetic Packaging From 2027"
  7. Global Cosmetics News: "Saudi Arabia Bans Syringe-Style Cosmetics From 2027"
  8. Sustainable Packaging Middle East & Africa: "Saudi Arabia bans syringe-style cosmetic packaging from 2027 with new labelling rules for ampoules, vials"

Frequently asked questions

What exactly did Saudi Arabia's SFDA ban on 12 August 2026?

SFDA issued a circular prohibiting the circulation of external-use cosmetic products packaged in forms resembling pharmaceutical injectables. Syringe-style applicators are banned outright, with no labeling fix available. Ampoules and vials remain permitted, but their inner and outer packaging must carry a new bilingual Arabic-and-English warning that the product is for external cosmetic use only and must not be injected.

Are cosmetic ampoules and vials banned in Saudi Arabia too?

No. Only syringe-style packaging is banned outright. Ampoules and vials, the format behind most "skin booster" and collagen-serum products, stay legal provided their packaging is updated with the new bilingual warning and marketing material does not state or imply the product can be injected or used with a skin-penetrating device.

What is the deadline for brands to comply, and does it cover products already on the market?

Manufacturers, importers and other establishments have until 31 December 2026 to withdraw noncompliant stock or bring packaging and labels into line. This covers products already in circulation, including those holding a valid SFDA marketing notification: there is no grandfather clause. The ban and labeling requirements take legal effect on 1 January 2027, with SFDA saying it will pursue legal action against noncompliant products and establishments after that date.

Related resources

Close-up of the blue foam inside of a bicycle helmet, a label with the CE mark, pictograms and sizes
Product Compliance14 March 2026 · 11 min read

Cosmetic Regulation by Country: EU vs US vs Japan vs Brazil vs China

A cosmetic product sold globally must comply with completely different regulatory frameworks in each market. The EU bans over 1,600 ingredients; the US bans 11. Japan requires quasi-drug classification for anti-aging claims. China mandates animal testing for imported ordinary cosmetics. This guide maps the key differences across five major markets.read ↗
Steel toaster opened up on a kitchen table, panel and screws beside it, a blue-handled screwdriver in a hand
Product Compliance27 April 2026 · 6 min read

When a lipstick becomes a legal risk: what 2025's cosmetic recalls reveal about product compliance

In 2024, cosmetics accounted for 36% of all alerts on EU Safety Gate: the leading category, ahead of toys, clothing and electronics. Three recent recalls (MCI/MI in leave-on creams, heavy metals in makeup, French PFAS law n°2025-188) show why compliance in cosmetics is not an event but a regulatory flow that has to be tracked across living annexes.read ↗
Tractor at dawn, a farmer from behind, blue tarp
Product Compliance18 July 2026 · 6 min read

Indonesia's halal certification deadline for cosmetics is 17 October 2026, but the rules defining a compliant ingredient supply chain are still open for public comment until 2 August

Under Indonesia's Government Regulation No. 42 of 2024, mandatory halal certification extends on 17 October 2026 from food and beverages to cosmetics, pharmaceuticals, traditional medicines, health supplements and other consumer goods. Most coverage treats this as a certification deadline. What it misses: BPJPH's administrative-sanctions regulation only came into force 5 June 2026, and the draft guidelines defining a compliant cosmetics ingredient supply chain, critical control points against mixing halal and non-halal materials, were only notified to the WTO 4 June, staying open for public comment until 2 August, eleven weeks before enforcement starts.read ↗
Grey electric fence energiser on a wooden post, a blue gate handle, sheep in the pasture behind
Product Compliance4 July 2026 · 6 min read

The UK bans Enzacamene from cosmetics on 15 July, and the same SKU can stay legal one border away, in Northern Ireland

From 15 July 2026, the UK bans the UV filter Enzacamene (4-MBC) in cosmetics and cuts the formaldehyde-release labelling threshold 50x, from 0.05% to 0.001%, under SI 2026/23; 16 more CMR substances are prohibited from 15 August. The nuance most coverage misses: this only applies to Great Britain. Northern Ireland stays on the EU’s own, separately timed cosmetics rules under the Windsor Framework: one SKU, two rulebooks.read ↗

something new in the works?

A scope and a price agreed for your product and markets.See the product in action↗
Cleo
pricingcase studyresourcesaboutbecome an expertfaqcontact

product compliance, handled.

anaelle@cleolabs.colinkedin ↗x ↗youtube ↗whatsapp ↗
© 2026 Cleo Corp SAS · Neuilly-sur-Seine
PrivacyTermsSecuritySite map
cleo / made to exist.